WR 279,396 topical cream

DRUG2 trials

Sponsors

U.S. Army Medical Research and Development Command

Conditions

Cutaneous Leishmaniasis

Phase 2

WR 279,396 Open Label Treatment Protocol in Tunisia

TerminatedNCT01494350

U.S. Army Medical Research and Development CommandCutaneous Leishmaniasis

Start: 2011-12-31End: 2012-06-30Updated: 2014-12-19

Phase 3

Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)

CompletedNCT00606580

U.S. Army Medical Research and Development CommandCutaneous Leishmaniasis

Start: 2008-01-31End: 2011-07-31Updated: 2014-07-14

Related Papers

Topical paromomycin with or without gentamicin for cutaneous leishmaniasis.

2013-02-01147 citations